

Audit Review Table				
Parkland Community Health Plan (Org ID: 19735, SubID: 11065, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2017; Date & Timestamp - 6/27/2018 2:54:19 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and				
Adult BMI Assessment (aba)		83.51%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
<i>BMI Percentile</i>		69.59%	R	Reportable
<i>Counseling for Nutrition</i>		73.24%	R	Reportable
<i>Counseling for Physical Activity</i>		66.67%	R	Reportable
Childhood Immunization Status (cis)				
<i>DTaP</i>		80.05%	R	Reportable
<i>IPV</i>		89.78%	R	Reportable
<i>MMR</i>		91.48%	R	Reportable
<i>HiB</i>		91.73%	R	Reportable
<i>Hepatitis B</i>		92.94%	R	Reportable
<i>VZV</i>		91.24%	R	Reportable
<i>Pneumococcal Conjugate</i>		80.29%	R	Reportable
<i>Hepatitis A</i>		90.51%	R	Reportable
<i>Rotavirus</i>		75.43%	R	Reportable
<i>Influenza</i>		45.74%	R	Reportable
<i>Combination #2</i>		76.40%	R	Reportable
<i>Combination #3</i>		73.97%	R	Reportable
<i>Combination #4</i>		73.24%	R	Reportable
<i>Combination #5</i>		65.69%	R	Reportable
<i>Combination #6</i>		39.90%	R	Reportable
<i>Combination #7</i>		65.21%	R	Reportable
<i>Combination #8</i>		39.66%	R	Reportable
<i>Combination #9</i>		36.50%	R	Reportable
<i>Combination #10</i>		36.25%	R	Reportable
Immunizations for Adolescents (ima)				
<i>Meningococcal</i>		90.75%	R	Reportable

<i>Tdap</i>		91.48%	R	Reportable
<i>HPV</i>		33.58%	R	Reportable
<i>Combination #1</i>		90.02%	R	Reportable
<i>Combination #2</i>		33.33%	R	Reportable
Lead Screening in Children (lsc)			NA	Small Denominator
Breast Cancer Screening (bcs)		48.15%	NA	Small Denominator
Cervical Cancer Screening (ccs)		69.34%	R	Reportable
Chlamydia Screening in Women (chl)				
<i>16-20 Years</i>		45.23%	R	Reportable
<i>21-24 Years</i>		57.59%	R	Reportable
<i>Total</i>		46.44%	R	Reportable
Effectiveness of Care: Respiratory				
Appropriate Testing for Children with Pharyngitis (cwp)	Y	83.64%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)		0.00%	NA	Small Denominator
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
<i>Systemic Corticosteroid</i>		100.00%	NA	Small Denominator
<i>Bronchodilator</i>		100.00%	NA	Small Denominator
Medication Management for People With Asthma (mma)	Y			
<i>5-11 Years: Medication Compliance 50%</i>		45.58%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		18.62%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		43.58%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		17.17%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		64.29%	NA	Small Denominator
<i>19-50 Years: Medication Compliance 75%</i>		42.86%	NA	Small Denominator
<i>51-64 Years: Medication Compliance 50%</i>			NA	Small Denominator
<i>51-64 Years: Medication Compliance 75%</i>			NA	Small Denominator
<i>Total: Medication Compliance 50%</i>		45.01%	R	Reportable
<i>Total: Medication Compliance 75%</i>		18.26%	R	Reportable
Asthma Medication Ratio (amr)	Y			
<i>5-11 Years</i>		66.65%	R	Reportable
<i>12-18 Years</i>		61.24%	R	Reportable

19-50 Years		42.86%	NA	Small Denominator
51-64 Years		0.00%	NA	Small Denominator
Total		64.55%	R	Reportable
Effectiveness of Care: Cardiovascular				
Controlling High Blood Pressure (cbp)		41.88%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	0.00%	NA	Small Denominator
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
Received Statin Therapy: 21-75 Years (Male)		100.00%	NA	Small Denominator
Statin Adherence 80%: 21-75 Years (Male)		50.00%	NA	Small Denominator
Received Statin Therapy: 40-75 Years (Female)		66.67%	NA	Small Denominator
Statin Adherence 80%: 40-75 Years (Female)		0.00%	NA	Small Denominator
Received Statin Therapy: Total		80.00%	NA	Small Denominator
Statin Adherence 80%: Total		25.00%	NA	Small Denominator
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing		86.05%	R	Reportable
HbA1c Poor Control (>9.0%)		56.98%	R	Reportable
HbA1c Control (<8.0%)		33.14%	R	Reportable
HbA1c Control (<7.0%)			NQ	Not Required
Eye Exam (Retinal) Performed		47.67%	R	Reportable
Medical Attention for Nephropathy		92.44%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		52.91%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
Received Statin Therapy		74.29%	R	Reportable
Statin Adherence 80%		53.85%	NA	Small Denominator
Effectiveness of Care: Musculoskeletal				
Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	66.67%	NA	Small Denominator
Effectiveness of Care: Behavioral				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment		50.55%	R	Reportable
Effective Continuation Phase Treatment		29.67%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			

<i>Initiation Phase</i>		24.90%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>		25.13%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	N			
<i>30-Day Follow-Up</i>			NB	No Benefit
<i>7-Day Follow-Up</i>			NB	No Benefit
Follow-Up After Emergency Department Visit for Mental Illness (fum)	N			
<i>30-Day Follow-Up</i>			NB	No Benefit
<i>7-Day Follow-Up</i>			NB	No Benefit
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)	N			
<i>30-Day Follow-Up: 13-17 Years</i>			NB	No Benefit
<i>7-Day Follow-Up: 13-17 Years</i>			NB	No Benefit
<i>30-Day Follow-Up: 18+ Years</i>			NB	No Benefit
<i>7-Day Follow-Up: 18+ Years</i>			NB	No Benefit
<i>30-Day Follow-Up: Total</i>			NB	No Benefit
<i>7-Day Follow-Up: Total</i>			NB	No Benefit
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	92.86%	NA	Small Denominator
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)			NA	Small Denominator
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)			NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y		NQ	Not Required
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
<i>1-5 Years</i>		17.24%	NA	Small Denominator
<i>6-11 Years</i>		21.51%	R	Reportable
<i>12-17 Years</i>		28.37%	R	Reportable

<i>Total</i>		24.24%	R	Reportable
Effectiveness of Care: Medication				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
<i>ACE Inhibitors or ARBs</i>		87.60%	R	Reportable
<i>Diuretics</i>		93.90%	R	Reportable
<i>Total</i>		90.15%	R	Reportable
Effectiveness of Care:				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		1.03%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	91.90%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	26.00%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		63.20%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y			
<i>1-5 Years</i>		0.00%	NA	Small Denominator
<i>6-11 Years</i>		1.71%	R	Reportable
<i>12-17 Years</i>		0.00%	R	Reportable
<i>Total</i>		0.91%	R	Reportable
Use of Opioids at High Dosage (uod)	Y	22.90	R	Reportable
Use of Opioids From Multiple Providers (uop)	Y			
<i>Multiple Prescribers</i>		320.51	R	Reportable
<i>Multiple Pharmacies</i>		134.62	R	Reportable
<i>Multiple Prescribers and Multiple Pharmacies</i>		70.51	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
<i>20-44 Years</i>		79.66%	R	Reportable
<i>45-64 Years</i>		81.92%	R	Reportable
<i>65+ Years</i>			NA	Small Denominator
<i>Total</i>		79.90%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				

12-24 Months		97.77%	R	Reportable
25 Months - 6 Years		91.04%	R	Reportable
7-11 Years		93.77%	R	Reportable
12-19 Years		93.51%	R	Reportable
Annual Dental Visit (adv)	N			
2-3 Years			NB	No Benefit
4-6 Years			NB	No Benefit
7-10 Years			NB	No Benefit
11-14 Years			NB	No Benefit
15-18 Years			NB	No Benefit
19-20 Years			NB	No Benefit
Total			NB	No Benefit
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	N			
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Total: Initiation of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Total: Engagement of AOD Treatment: 13-17 Years</i>			NB	No Benefit
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years</i>			NB	No Benefit

<i>Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Total: Initiation of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Total: Engagement of AOD Treatment: 18+ Years</i>			NB	No Benefit
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: Total</i>			NB	No Benefit
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: Total</i>			NB	No Benefit
<i>Opioid abuse or dependence: Initiation of AOD Treatment: Total</i>			NB	No Benefit
<i>Opioid abuse or dependence: Engagement of AOD Treatment: Total</i>			NB	No Benefit
<i>Other drug abuse or dependence: Initiation of AOD Treatment: Total</i>			NB	No Benefit
<i>Other drug abuse or dependence: Engagement of AOD Treatment: Total</i>			NB	No Benefit
<i>Total: Initiation of AOD Treatment: Total</i>			NB	No Benefit
<i>Total: Engagement of AOD Treatment: Total</i>			NB	No Benefit
Prenatal and Postpartum Care (ppc)				
<i>Timeliness of Prenatal Care</i>		86.37%	R	Reportable
<i>Postpartum Care</i>		65.94%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	N			
<i>1-5 Years</i>			NB	No Benefit
<i>6-11 Years</i>			NB	No Benefit
<i>12-17 Years</i>			NB	No Benefit
<i>Total</i>			NB	No Benefit
Utilization				
Well-Child Visits in the First 15 Months of Life (w15)				
<i>0 Visits</i>		1.22%	R	Reportable
<i>1 Visit</i>		0.73%	R	Reportable
<i>2 Visits</i>		0.97%	R	Reportable
<i>3 Visits</i>		2.68%	R	Reportable
<i>4 Visits</i>		10.71%	R	Reportable
<i>5 Visits</i>		19.71%	R	Reportable

6+ Visits		63.99%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		81.02%	R	Reportable
Adolescent Well-Care Visits (awc)		70.56%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NQ	Not Required
Ambulatory Care: Disabled (ambc)			NQ	Not Required
Ambulatory Care: Other (ambd)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NQ	Not Required
Identification of Alcohol and Other Drug Services: Total (iada)	N		NB	No Benefit
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N		NB	No Benefit
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N		NB	No Benefit
Identification of Alcohol and Other Drug Services: Other (iadd)	N		NB	No Benefit
Mental Health Utilization: Total (mpta)	N		NB	No Benefit
Mental Health Utilization: Dual Eligibles (mptb)	N		NB	No Benefit
Mental Health Utilization: Disabled (mptc)	N		NB	No Benefit
Mental Health Utilization: Other (mptd)	N		NB	No Benefit
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y		NQ	Not Required
Antibiotic Utilization: Disabled (abxc)	Y		NQ	Not Required
Antibiotic Utilization: Other (abxd)	Y		NQ	Not Required
Standardized Healthcare-Associated Infection Ratio (hai)			NQ	Not Required

Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive				
Board Certification (bcr)			NQ	Not Required
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NQ	Not Required
Enrollment by Product Line: Disabled (enpc)			NQ	Not Required
Enrollment by Product Line: Other (enpd)			NQ	Not Required
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			R	Reportable
Race/Ethnicity Diversity of Membership (rdm)			R	Reportable
Total Membership (tln)			R	Reportable
Measures Collected using Electronic				
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Utilization of PHQ-9: Total Total</i>			NR	Not Reported
Depression and Remission or Response for Adolescents and Adults (drr)				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Postive Screen: Total Total</i>			NR	Not Reported